Inside the body: study reveals how wegovy and mounjaro change your metabolism over 6 months.

NCT ID NCT07041983

ENROLLING_BY_INVITATION Disease control Sponsor: University of Pisa Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 30 adults with obesity who are starting anti-obesity medications like Wegovy or Mounjaro. Researchers will measure how these drugs affect 24-hour energy expenditure and body composition (fat vs. muscle) over 6 months using a metabolic chamber and DXA scans. The goal is to understand the long-term metabolic changes behind weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Wegovy) and Tirzepatide (Mounjaro)
What this could lead to: If successful, this could clarify how these weight-loss drugs change the body's energy use and fat loss, helping doctors personalize obesity treatment.
What could go wrong: This is a small, early-stage study with only 30 participants and no control group, so results may not apply to everyone. It measures metabolism changes, not long-term weight loss or health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

university hospital of Pisa

Pisa, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.